Clinical Trial Update: Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on Human cell line-derived recombinant Factor VIII in previously untreated patients with severe Hemophilia A; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Human cell line-derived recombinant Factor VIII (Human-cl-rhFVIII)

Snippet

Sponsor: Octapharma | Conditions: Severe Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2019-10-21